Project Grant R44AG072981
- The National Institute on Aging awarded $1.499 million to S-3 Research LLC on September 20, 2025, under the Aging Research program (CFDA 93.866) to develop a multi-modal digital tool improving diversity and inclusivity in Alzheimer's Disease and Related Dementias (ADRD) clinical trial participation. S-3 Research LLC will develop an integrated mobile application, website, and artificial intelligence chatbot designed to enhance education, recruitment, and enrollment of older adults in ADRD...
- The National Institute on Aging awarded Hido Technologies, Inc. $3,694,635 on September 20, 2025, under the Aging Research program (CFDA 93.866) to conduct a Phase II randomized controlled trial validating the Homecare platform and pharmacy distribution system for improving medication adherence in persons with dementia. Homecare is an internet-connected self-medicating device integrated with a pharmacy distribution system that uses video direct observed therapy to monitor medication...
- The National Institute on Aging awarded One Health Studio LLC $948,184 on September 20, 2025, under the Aging Research program (CFDA 93.866) to develop and evaluate the FLOURISH ALL platform, an AI-enabled digital health solution designed to reduce Alzheimer's disease and related dementia risk by managing stress and promoting healthy behaviors in midlife women. The project addresses the disproportionate burden of Alzheimer's disease on women, who account for two-thirds of all patients. The...
- Federal Cooperative Agreement Award Summary Biosensics LLC received a $5.17 million Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with completion expected August 31, 2029. The award supports development and qualification of digital health monitoring technologies for Progressive Supranuclear Palsy (PSP) and Dementia with Lewy Bodies (DLB), two neurodegenerative conditions lacking FDA-approved treatments and...
- The National Institute on Aging awarded $1,519,197 to Healthy Design LTD. CO. on September 22, 2025, under the Aging Research program (CFDA 93.866) to develop a novel continuous predictive wearable agitation monitor using actigraphy and artificial intelligence for hospitalized older adults to prevent delirium and dementia. The device delivers real-time monitoring and alerting to detect agitation in confused patients at risk for equipment dislodgement, replacing the current standard of...
- The National Institute on Aging awarded $673,378 to Seeinme Inc. on September 22, 2025, under the Aging Research program (CFDA 93.866) to develop and test SEEINME, a consumer-generated, HIPAA-compliant digital personal health profile for people with dementia. SEEINME is a Phase 1 Small Business Innovation Research (R43) project designed to create a secure, interactive biopsychosocial profile that persons with dementia and their informal caregivers can author, edit, and share with assisted living...
- The National Institute on Aging awarded Aster Labs, Inc. $499,943 on September 15, 2025, under the Aging Research program (CFDA 93.866) to design and construct a wearable gait-monitoring device for continuous home-based assessment of health decline in Black adults with Alzheimer's disease and related dementias. The device will measure gait patterns including stride and speed throughout the day to provide clinicians and caregivers with early indication of functional decline and disease...
- The National Institute on Aging awarded Bellage Inc. $499,396 under the Aging Research program (CFDA 93.866) on September 20, 2025, to develop and refine AWC-PRIME, a companion application that supports care partners of people living with Alzheimer's disease and related dementia. The application will identify care partners' self-care and stress-management needs, facilitate goal-setting through motivational interviewing, develop personalized self-management plans grounded in behavioral theory,...
- This Project Grant award of $4,787,820.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a better understanding of the individual- and system-level characteristics that influence diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD), and how diagnosis can moderate the effects of cognitive decline on employment, future care, and quality of life. The key objectives are to: 1) examine whether older adults experiencing...
- The National Institute for Minority Health and Health Disparities awarded Amissa Inc. $504,222 on August 17, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to develop digital biomarkers for detecting and monitoring vasomotor symptoms in perimenopausal Latina women using Apple Watch data. The Phase I Small Business Innovation Research project, HERMOSA, will create clinical-grade digital biomarkers to assess hot flashes and night sweats in a population that...
EMPOWERING ADVANCED ALZHEIMERS DISEASE AND DEMENTIA RESEARCH THROUGH REMOTE PATIENT MONITORING AND CLOUD-CONNECTED WEARABLE DEVICES - PROJECT SUMMARY LAST YEAR, THE CARE AND TREATMENT OF ROUGHLY 6 MILLION PEOPLE DIAGNOSED WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS COST THE U.S. APPROXIMATELY $593 BILLION DOLLARS. THE TREMENDOUS COSTS ASSOCIATED WITH ALZHEIMER'S DISEASE INCLUDE DIRECT MEDICAL COSTS, SUCH AS DOCTOR VISITS, HOSPITAL STAYS, AND PRESCRIPTION DRUGS, AS WELL AS INDIRECT COSTS SUCH AS LOST WAGES AND PRODUCTIVITY FOR BOTH THE AFFECTED INDIVIDUALS AND THEIR CAREGIVERS. ACCORDING TO THE ALZHEIMER'S ASSOCIATION, THE TOTAL COST OF CARE FOR THE ESTIMATED 13 MILLION INDIVIDUALS WITH ALZHEIMER'S AND OTHER DEMENTIAS IN THE UNITED STATES BY 2050 IS PROJECTED TO REACH $1.1 TRILLION. EMERGING LIFESTYLE INTERVENTION RESEARCH IS TESTING WHETHER CHANGES IN PHYSICAL EXERCISE, SLEEP, SOCIALIZATION, AND SEDENTARY BEHAVIORS HAVE AN IMPACT ON DISEASE ONSET AND PROGRESSION OF SYMPTOMS THROUGHOUT THE LIFESPAN. UNFORTUNATELY, OBTAINING REAL- WORLD PATIENT-GENERATED HEALTH AND BEHAVIOR INFORMATION TO SUPPORT THIS RESEARCH FROM AGING POPULATIONS IS CHALLENGING AND OFTEN RELIES ON UNRELIABLE SELF-REPORTING. AFTER YEARS OF MEETINGS WITH 70+ INVESTIGATORS AND SCIENTISTS AT THE NIH, THE NATIONAL ALZHEIMER'S COORDINATING CENTER, ALZHEIMER'S DISEASE RESEARCH CENTERS, NUMEROUS UNIVERSITIES, AND THE ALZHEIMER'S ASSOCIATION WE DETERMINED AND AGREED THAT A CONSOLIDATED DATABASE OF REAL-LIFE, DIGITAL HEALTH INFORMATION DOES NOT EXIST FOR ALZHEIMER'S AND DEMENTIA RESEARCH. DURING AMISSA'S SBIR PHASE I, WE CREATED SOFTWARE TO MEASURE AND COLLECT PHYSIOLOGICAL HEALTH DATA PASSIVELY AND UNOBTRUSIVELY FROM NON-STIGMATIZING SMARTWATCHES INCLUDING THE APPLE WATCH AND SAMSUNG GALAXY WATCH. THIS SBIR PHASE II PROJECT IS CRITICAL TO EXPANDING THAT R & D AND IMPROVING REMOTE HEALTH MEASUREMENTS, COLLECTING AND SHARING RICH DIGITAL HEALTH DATASETS, AND IDENTIFYING POTENTIAL DIGITAL BIOMARKERS THAT CORRELATE TO DISEASE DETECTION, PROGRESSION, AND PREVENTION. OUR TWO SOFTWARE INNOVATIONS WILL ENABLE SCIENTIFIC RESEARCHERS ACROSS THE WORLD TO UTILIZE CONSUMER-GRADE SMARTWATCHES AS PASSIVE REMOTE PATIENT MONITORING SOLUTIONS. RESEARCHERS, LABS, UNIVERSITIES, AND HEALTHCARE PRACTITIONERS WILL BE ABLE TO CREATE ACCOUNTS ON OUR PLATFORM, ENROLL HER/HIS VOLUNTEER SUBJECTS/PATIENTS FOR A STUDY, AND USE OUR FREE SOFTWARE TO COLLECT LONGITUDINAL INFORMATION INCLUDING HEALTH VITALS AND BEHAVIOR DATA. SPECIFIC AIM 1: DEVELOP A RESEARCH PLATFORM AND REAL-WORLD HEALTH DATA MARKETPLACE TO SUPPORT ACADEMIC RESEARCH AND ENTERPRISE PARTNERSHIPS. DURING PHASE II R & D, AMISSA HEALTH WILL COLLABORATE WITH EXPERTS FROM WAKE FOREST UNIVERSITY, HARVARD MEDICAL SCHOOL, THE MASSACHUSETTS ALZHEIMER'S DISEASE RESEARCH CENTER, ATRIUM/ADVOCATE HEALTH, EDGE ANALYTICS, AND MICROSOFT TO DEVELOP THE FIRST SHARED RESEARCH PLATFORM THAT WILL APPLY LONGITUDINAL, REAL-WORLD, WEARABLE SENSOR MEASUREMENTS TO ADVANCE RESEARCH OF DEMENTIA-RELATED DIGITAL BIOMARKERS AND BEHAVIORAL INTERVENTIONS. SPECIFIC AIM 2: WORKING WITH EDGE ANALYTICS, A HEALTHCARE-FOCUSED DATA SCIENCE FIRM THAT DEVELOPS PROTOTYPES TO PRODUCTION-READY ALGORITHMS, WE WILL FINE- TUNE EDGE COMPUTING ALGORITHMS AND SMARTWATCH SENSOR DATA COLLECTION AND COMPRESSION TECHNIQUES TO MAXIMIZE REAL-TIME HEALTH DATA MEASUREMENT AND COLLECTION AREAS WITH POOR CELLULAR AND/OR WI-FI NETWORKS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 8/5/25 | ||
| Not listed | $1.4m | 9/24/24 |